Campone M.,Institute du Cancer Nantes Atlantiques |
Campone M.,French Institute of Health and Medical Research |
Berton-Rigaud D.,Institute du Cancer Nantes Atlantiques |
Bourbouloux E.,Institute du Cancer Nantes Atlantiques |
And 3 more authors.
Bulletin du Cancer | Year: 2011
The molecular classification of Perou and Sørlie breast tumors has to streamline, systematize and make effective use of targeted therapies against specific molecular subtypes, including breast HER2 positive. Trastuzumab and lapatinib are currently the two therapies targeting HER2, which have demonstrated their effectiveness in clinical practice. This literature review aims to make the data points on pertinent and useful data for physicians in daily. ©John Libbey Eurotext. Source